A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects
HSVHIV
1 other identifier
observational
50
1 country
1
Brief Summary
This study is an observational, cohort, prospective study looking at the frequency of Herpes Simplex Virus (HSV) 1 and or 2 outbreaks in HIV positive patients who's HIV virus is controlled on highly active anti-retroviral therapy. We will be enrolling fifty (50) patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2022
CompletedFirst Submitted
Initial submission to the registry
April 9, 2023
CompletedFirst Posted
Study publicly available on registry
April 21, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2025
CompletedApril 21, 2023
April 1, 2023
2.8 years
April 9, 2023
April 9, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Epidemiology
The frequency of HSV outbreaks in HIV positive patients.
48 weeks
Secondary Outcomes (1)
Co Morbidity
48 weeks
Interventions
We will be drawing blood for verify HIV status, HSV 1 or 2 antibodies, CD4 and HIV-PCR
Eligibility Criteria
Patients who are positive for HIV antibodies and IgG or IgM antibodies to Herpes Simplex Virus 1 or Herpes Simplex Virus 2
You may qualify if:
- Subject must be 18 years or older at the time of screening
- Males, Females, Transgender Male and Transgender Females
- HIV positive
- Positive antibody to HSV- 1/and or HSV-2
- If Female of child baring potential, documented negative pregnancy test at the time of screening.
You may not qualify if:
- Active opportunistic infection
- Current chemotherapy
- Unable to give informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Global Research Institutelead
- Rational Vaccines Inccollaborator
Study Sites (1)
Global Research Institute
Los Angeles, California, 90036, United States
Biospecimen
We are retaining patient serum
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 9, 2023
First Posted
April 21, 2023
Study Start
April 1, 2022
Primary Completion
December 31, 2024
Study Completion
April 1, 2025
Last Updated
April 21, 2023
Record last verified: 2023-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
- Time Frame
- At conclusion of the study
- Access Criteria
- Total Access
Share with Rational Vaccine